



NEWS RELEASE  
FOR IMMEDIATE RELEASE

TSX: AMF

**AMORFIX vCJD ASSAY ACHIEVES 100% SENSITIVITY AND 100% SPECIFICITY ON 1,000 FRESH SAMPLES FROM UK BLOOD DONORS**

**TORONTO, ON, October 17, 2008** – Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, today announced the best sensitivity and specificity ever reported using its EP-vCJD™ Blood Screening Assay to test fresh blood plasma samples from anonymous UK blood donors. Amorfix completed this testing in the laboratories of the National Institute for Biological Standards and Control (NIBSC) in the United Kingdom.

Amorfix tested 1,000 fresh blinded human plasma samples which included samples that were spiked with vCJD brain prions and normal brain. The EP- vCJD™ Blood Screening Assay scored 100% sensitivity for all spiked samples down to a 1 in 100,000 dilution of 10% brain homogenate (1/1,000,000 dilution of vCJD brain). The specificity for all samples was 99.3% on initial testing and 100% on repeat reactive testing.

“A major concern for screening human blood donors for vCJD is finding false positives and then erroneously notifying blood donors and excluding them from future donations,” said Dr. George Adams, Chief Executive Officer of Amorfix. “The UK authorities have put forward a 99.9% specificity as an acceptable performance for a vCJD test on blood donor samples and these first results suggest we can meet or exceed this requirement.”

NIBSC has asked us to continue testing samples to verify the results and to determine if frozen samples can similarly be used, as all vCJD patient samples are frozen. The current testing was conducted with kits manufactured over 12 months ago which continue to demonstrate excellent shelf life and stability.

**About Amorfix**

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer's Disease, Parkinson's Disease and variant Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection™ (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and the ability to identify AMPs and understand their structure and mechanism of folding are the first steps to developing new treatments for these devastating diseases. Amorfix's lead programs are a diagnostic blood screening test for vCJD and a therapy for ALS.

*This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*

- 30 -

**For more information, please contact:**

Dr. George Adams President & Chief Executive Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6959 Fax: (416) 847-6899 george.adams@amorfix.com	James Parsons Chief Financial Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6929 Fax: (416) 847-6899 james.parsons@amorfix.com
---	---